| Name | Targets | Structure | Type of Structure /Function /Side effects | Company /Phase |
| SAR-302503/ TG-101348 | JAK2/RET |  |
Aminopyrimidines; Drug of Ph chromosome-negative myeloproliferative neoplasms [44,45]; Nausea, diarrhoea, anaemia [46] |
Sanofi- Aventis Phase II |
| LY-2784544 | JAK2 |  |
Imidazolepyrazole; Polycythaemia vera, essential- Thrombocythaemia; Tumour lysis syndrome [47] |
Lilly Phase II |
| BMS-911453 | JAK2 |  |
Pyrroleimidazopyridine; Inhibited CD34 + from bone marrow fibrosis; Not determined [48] |
BRistol- MyeRsSquibb Phase I |
| XL-019 | JAK2 |  |
Pyrrole amides; Myeloproliferative disorders [49]; Phenomenon of central and peripheral neuropathy |
Exelixis PhaseI (termination) |
| AG-490 | JAK2 |  |
Styrene amine; Specific JAK2 antagonist [50]; Tools compound |
No reports of clinical studies |